Targeting Inflammation: Recent Advances in Antiarthritic Therapies from Natural and Synthetic Origins

Kale Abhijeet B[1], Bindu A. U[2], Suryawanshi Sandeep B[3]
[1,3] *Research Scholar. Department of Pharmacology, Gurukrupa Sevabhavi Sanstha's Gurukrupa Institute of Pharmacy, Majalegaon, Beed*
[2]*Research guide, Department of Pharmacology, Gurukrupa Sevabhavi Sanstha's Gurukrupa Institute of Pharmacy, Majalegaon, Beed*

***Abstract*—Arthritis, particularly rheumatoid arthritis and osteoarthritis, remains a major global health challenge owing to its chronic, inflammatory, and degenerative nature. Current treatments aim to reduce inflammation and prevent joint damage, but often have limitations, such as side effects and cost. This review explores recent developments in antiarthritic therapies, focusing on both natural (plant-based compounds and nutraceuticals) and synthetic (NSAIDs, DMARDs, and biologics) approaches. Emphasis is placed on the molecular targets, mechanisms of action, and comparative efficacy. The integration of traditional remedies and modern pharmacology presents new hope for safe, effective, and affordable management of arthritis.**

***Index Terms*—Anti-arthritic, inflammatory, natural compounds, synthetic drugs, rheumatoid arthritis, phytochemicals, NSAIDs, DMARDs, cytokines.**

I. INTRODUCTION

Arthritis is a general term that refers to inflammation of the joints that causes symptoms such as pain, swelling, stiffness, and reduced range of motion. Among various types of arthritis, rheumatoid arthritis (RA) and osteoarthritis (OA) are the most prevalent. Rheumatoid arthritis (RA) is a chronic autoimmune disease that is characterized by inflammation and joint damage. It affects synovial joints, leading to the destruction of cartilage and bone tissue due to chronic inflammation of the joint lining, known as the synovium. This inflammation results in pain, swelling, and stiffness and usually affects the joints symmetrically. RA is associated with significant health risks including cardiovascular disease, respiratory issues, osteoporosis, and increased mortality. The management of RA has significantly advanced owing to early diagnosis and aggressive treatment using disease-modifying antirheumatic drugs (DMARDs), which have improved patient outcomes (Brown et al., 2024; Sparks, 2019). Osteoarthritis, on the other hand, is a degenerative joint disease traditionally characterized by "wear and tear" of the articular cartilage and changes in surrounding tissues, including subchondral bone thickening and osteophyte formation. OA primarily affects weight-bearing joints such as the hips and knees, leading to significant pain and disability. Unlike RA, OA is not driven by autoimmune processes but rather by mechanical and biological factors. Risk factors include age, obesity, joint injury, and repetitive stress on joints. The treatment of OA mainly focuses on managing symptoms and improving joint function through lifestyle changes, pain management, and surgical intervention in severe cases (Mobasheri, 2013; Litwic et al., 2013). Both RA and OA present distinct pathophysiological mechanisms and require tailored therapeutic approaches to manage their progression and improve the patients' quality of life. These findings highlight the diverse nature of arthritis and the need for continued research to understand and effectively treat these conditions.

II. ROLE OF CHRONIC INFLAMMATION IN PATHOGENESIS

Chronic inflammation is increasingly being recognized as a pivotal factor in the pathogenesis of various chronic diseases. Its role extends to metabolic disorders, cardiovascular diseases, neurodegenerative conditions, and cancers. Unlike acute inflammation, which serves as a protective response to injury or

infection, chronic inflammation is characterized by persistent low-grade inflammation, which can lead to tissue damage and disease progression (1). One of the mechanisms by which chronic inflammation contributes to the disease is oxidative stress, which creates a feedback loop that sustains the inflammatory processes. In this loop, reactive oxygen species (ROS) promote the release of pro-inflammatory cytokines, further amplifying oxidative stress and inflammation (2). This cycle is particularly evident in metabolic disorders such as obesity and diabetes, where inflammatory responses are exacerbated by metabolic dysfunction (3).Chronic inflammation also plays a role in altering immune cell function. For example, neutrophils, which typically help resolve inflammation, can contribute to chronic inflammatory processes and influence diseases such as atherosclerosis and diabetes (1). Changes in N-glycosylation during chronic inflammation further affect immune cell interactions and functions, implicating these modifications in disease progression (4). Bioactive lipids are also critical for the regulation of inflammatory processes. These lipids can transition inflammation from acute to chronic states when pro-inflammatory lipids are persistently active, or when the roles of anti-inflammatory lipids are impaired. This transition has been linked to several chronic conditions including rheumatoid arthritis, diabetes, and multiple sclerosis (5). Moreover, lifestyle and dietary factors can influence chronic inflammatory states. For instance, certain dietary components such as those found in eggs have been shown to modulate inflammatory pathways. Their effects on inflammation can vary depending on the population, with potential implications for dietary recommendations to mitigate chronic disease risk (6). Targeting inflammation remains a significant focus in therapeutic interventions. The development of cyclooxygenase-2 (COX-2) inhibitors exemplifies the efforts to address chronic inflammation. These inhibitors aim to reduce the gastrointestinal side effects associated with traditional non-steroidal anti-inflammatory drugs while attenuating the prolonged pro-inflammatory states seen in various diseases (7). In summary, chronic inflammation plays a central role in the pathogenesis of several diseases. Understanding the intricate mechanisms underlying chronic inflammation, such as oxidative stress, immune cell dysregulation, and metabolic effects, is crucial for developing effective therapeutic strategies to combat the progression of inflammation-related chronic diseases. Although I cannot generate a full essay, there is information regarding the role of chronic inflammation in disease pathogenesis based on the available literature.

III. NEED FOR EFFECTIVE ANTI-INFLAMMATORY THERAPIES

The need for effective anti-inflammatory therapies is evident across a range of chronic diseases, including inflammatory bowel disease (IBD), psoriasis, gouty arthritis, and coronary atherosclerosis. These conditions often result from or exacerbate inflammation, necessitating innovative therapeutic strategies for their effective management. In the context of IBD, anti-TNF therapies have shown significant promise for managing inflammation, achieving clinical and endoscopic remission, and reducing the need for surgery. However, these therapies are not universally effective, and some patients experience loss of responsiveness over time. Identifying predictive biomarkers for therapeutic responses can help optimize treatment and personalized approaches for better outcomes (8). Similarly, psoriasis, a chronic inflammatory skin condition, highlights the urgency for novel therapeutics owing to the limited effectiveness and adverse effects of current treatments. Chrysin, a plant flavonoid, has been shown to have potential anti-inflammatory effects by attenuating key inflammatory pathways such as MAPK and NF-κB, offering a new avenue for treatment development (9). The need for alternatives to conventional therapies, which often have side effects, is critical in gouty arthritis. Zanthoxylum piperitum Benn. showed promise in reducing inflammation through the NLRP3 inflammasome pathway, potentially offering a safer treatment approach (10). Coronary atherosclerosis, which is characterized by lipid-driven inflammation, also benefits from anti-inflammatory drugs. Despite their effectiveness, these treatments face challenges, such as cost, adverse effects, and identification of patients who will most benefit. There is ongoing research to improve these therapies by exploring both traditional and novel anti-inflammatory approaches (11). The development of

effective anti-inflammatory therapies is crucial for managing these conditions. Novel therapeutic strategies, including phytochemicals, targeted therapies, and new drug delivery systems, are currently under investigation to address the limitations of current treatments and improve patient outcomes. These advances underscore the significant role of inflammation in disease pathogenesis and the potential of anti-inflammatory therapies to enhance the quality of life of patients with chronic inflammatory conditions.

IV. IMPORTANCE OF EXPLORING BOTH NATURAL AND SYNTHETIC SOURCES

The exploration of both natural and synthetic sources is vital because of the unique advantages and challenges each present and their combined potential for advancing various fields, including drug development, sustainable technologies, and scientific research. Natural sources, such as plants, fungi, and bacteria, are rich in bioactive compounds that have been the foundation of numerous therapeutic agents. These natural materials are abundant, cost-effective, and renewable, making them attractive for sustainable development. For example, natural polysaccharides are extensively used in pharmaceuticals because of their biocompatibility and biodegradability, offering potential for drug delivery and biomedicine (12). Moreover, the use of natural materials in organic solar cells highlights their potential as environmentally friendly and cost-effective energy sources (13). However, synthetic sources offer controlled and versatile building blocks for scientific advancement. Synthetic macrocycles, such as pillarenes, have shown immense potential in molecular recognition and self-assembly, which are crucial for supramolecular chemistry and materials science (14). Additionally, synthetic hydrogels, inspired by natural materials, aim to mimic the extracellular matrix for biomedical applications, highlighting the interplay between synthetic and natural elements to overcome the specific limitations of natural biomaterials (15).The combination of natural and synthetic sources is critical for addressing the global challenges. For instance, modern computational chemistry leverages both of these sources to develop new drugs by elucidating the chemical structures of small organic molecules from both natural and synthetic origins (16). Despite the preference for natural products owing to their perceived safety, empirical studies indicate that synthetic products might offer better efficacy and safety in certain contexts. For example, a study of pesticides revealed that some synthetic insecticides pose less environmental risk than their organic counterparts, challenging the assumption that natural products are always safer (17). In conclusion, exploring both natural and synthetic sources is essential for innovation and advancement across disciplines. Synergy between these sources can lead to sustainable and efficient solutions for health, technology, and environmental conservation.

V. NATURAL ANTIARTHRITIC THERAPIES:

Natural antiarthritic therapies, often encompassed within complementary and alternative medicine (CAM), are widely adopted by individuals seeking alternative or adjunctive approaches to conventional arthritis treatment. These therapies include various mind-body interventions, herbal remedies, dietary supplements, acupuncture, and lifestyle modifications. Mind-body interventions such as yoga and meditation have gained popularity in the management of rheumatoid arthritis (RA). Clinical trials have suggested that these therapies can alleviate pain, improve mood, and enhance energy levels, although the quality of evidence remains low (18). Similarly, exercise has been shown to improve functional status in both RA and spondyloarthritis, although evidence regarding other therapies such as acupuncture and dietary interventions is less robust and varies in certainty (19). Herbal and dietary supplements continue to play significant roles in the management of arthritis. Products such as ginger, turmeric, and formulations based on phenolic compounds, flavonoids, and carotenoids have been highlighted for their potential to modulate inflammatory pathways, thereby alleviating the symptoms of RA (20). Moreover, specific dietary approaches such as Mediterranean and vegan diets may potentially modulate inflammatory processes and improve disease outcomes, although more extensive clinical research is needed to confirm these effects (20). Acupuncture is another widely adopted CAM approach, with systematic reviews supporting its efficacy in reducing osteoarthritis-related pain.

However, for rheumatoid arthritis pain, only very low certainty evidence exists, suggesting improvements. Accordingly, more high-quality studies are necessary to establish firm conclusions regarding its effectiveness. In addition to these therapies, recent studies of natural product extracts have explored their mechanistic roles in arthritis management using in silico, in vivo, and in vitro methods. These studies focused on how natural compounds might influence signaling pathways and reduce joint inflammation, revealing a promising area for further research (21). Despite these promising insights, many CAM therapies lack strong and consistent evidence, underlining the need for additional research to ascertain their efficacy and safety. Given the widespread interest in and adoption of these therapies, it is critical for healthcare professionals to be informed about CAM approaches to effectively guide patients with arthritis (22).

VI. PLANT-DERIVED COMPOUNDS

Plant-derived compounds have shown promising potential in the treatment and management of different forms of arthritis, including osteoarthritis (OA) and rheumatoid arthritis (RA). These compounds are recognized for their anti-inflammatory, antioxidant, and immunomodulatory properties, which play crucial roles in alleviating symptoms and potentially modifying disease progression.In the context of osteoarthritis, bioactive compounds from plants are utilized for their tissue-protective properties. These compounds help regulate the inflammatory processes and metabolic pathways involved in OA, which can lead to pain relief and slow disease progression (23). Natural compounds extracted from plants have been found to possess anti-inflammatory, antioxidative, and immunomodulatory properties. However, the uneven quality and poor bioavailability of commercially available preparations present challenges that future research should address (24).Specific plant-derived compounds, such as lignans, have historically been used to manage pain associated with rheumatoid arthritis due to their immunosuppressive activity (25). Black cumin (Nigella sativa) is another plant known for its therapeutic effects, which include anti-inflammatory and immunomodulatory properties that help in the treatment of autoimmune diseases such as RA (26).Moreover, the diverse mechanisms of action of plant secondary metabolites target the various molecular systems involved in RA. These include phenols, flavonoids, chalcones, xanthones, terpenoids, alkaloids, and glycosides, which have demonstrated significant anti-inflammatory and immunosuppressive activities in experimental studies (27). Additionally, novel therapeutic nanoagents developed from herbal medicine-derived carbon quantum dots have shown promising results in reducing inflammation and improving joint lubrication in RA models (28).In summary, plant-derived components hold great promise for the management of arthritis, offering potential alternatives to conventional treatments, which often have significant side effects. Continuous research is essential to improve the formulation, bioavailability, and understanding of the mechanisms of these compounds to maximize their therapeutic potential in arthritis treatment.

Curcumin, Boswellic acid, Withaferin A, Resveratrol, and Quercetin have shown promising therapeutic potential in the management of arthritis, owing to their anti-inflammatory and antioxidant properties.

Curcumin: This compound, primarily found in turmeric, has been extensively studied for its anti-inflammatory effects. It modulates inflammatory cytokines and signaling pathways that are crucial in the development and progression of arthritis. Studies have suggested that curcumin can significantly reduce inflammation and inhibit the activity of enzymes involved in the inflammatory process (29).

Boswellic acid: Extracted from the resin of Boswellia serrata, Boswellic acid has been investigated for its potential in reducing inflammation and improving joint function in arthritis. It is particularly important to inhibiting the 5-lipoxygenase enzyme, which plays a role in the biosynthesis of inflammatory mediators (29).

Withaferin A: While specific data on Withaferin A in arthritis wasn't detailed in the provided context, it is known for its immunomodulatory and anti-inflammatory properties, which are beneficial in managing symptoms of inflammatory diseases, including arthritis.

Resveratrol: This polyphenolic compound is well-regarded for its antioxidant capabilities. It reduces the production of reactive oxygen species and modulates inflammation, thus potentially playing a role in reducing joint damage and maintaining cartilage homeostasis in arthritis models (30).

Quercetin: Known for its capacity to suppress inflammatory cytokines and pathways, quercetin is beneficial in reducing the inflammatory processes associated with rheumatoid arthritis. Its effectiveness has been attributed to its ability to inhibit specific inflammatory mediators such as TNF-α and IL-6 (29). Despite their potential benefits, consistency in product quality and standardized dosages for these supplements remain areas of concern. High-quality randomized controlled trials are necessary to establish definitive guidelines for their use as adjunctive treatments in arthritis, ensuring efficacy and safety in broader patient populations (29).

VII. TRADITIONAL SYSTEMS OF MEDICINE

Polyherbal formulations in traditional systems of medicine, such as Ayurveda and Traditional Chinese Medicine (TCM), have been found to be significant in managing arthritis, particularly rheumatoid arthritis. Ayurveda employs a holistic approach, utilizing combinations of various herbs known as Rasayanas, to alleviate inflammation and oxidative stress associated with arthritis. These formulations are known to reduce joint pain, tenderness, and swelling, as well as improve mobility by modulating inflammatory pathways, enhancing antioxidant status, and inhibiting pro-inflammatory markers like NF-κB, cytokines, and COX-2 (31) (32). TCM uses a mixture of Chinese herbal medicines (CHMs) tailored to treat different subtypes of rheumatoid arthritis. These formulations contain bioactive compounds, such as alkaloids, flavonoids, and saponins, which have been shown to inhibit synovitis and reduce the secretion of pro-inflammatory factors, thereby mitigating the abnormal immune response and associated symptoms in arthritis. The use of CHM in TCM for arthritis involves an individualized approach known as pattern differentiation, which optimizes treatment according to specific patient symptoms (33) (34). Although both systems show promising results in the management of arthritis through polyherbal formulations, challenges remain in validating the synergistic effects and clinical relevance of these formulations owing to methodological complexities and variability in traditional diagnostic approaches (34). Nonetheless, the potential of these time-tested systems to contribute to arthritis treatment highlights the need for further research to integrate these approaches into modern therapeutic practice.

VIII. MECHANISMS OF ACTION

Rheumatoid arthritis (RA) is a complex autoimmune disorder characterized by chronic joint inflammation and eventual joint erosion if untreated. The underlying mechanisms of action in arthritis treatment, especially RA, involve targeting specific pathways and mediators of the immune response that drive inflammation and destruction of joint tissues.One of the primary strategies for RA treatment is the use of disease-modifying antirheumatic drugs (DMARDs), which are designed to slow disease progression and prevent joint and tissue damage. These drugs included methotrexate, hydroxychloroquine, sulfasalazine, and leflunomide. DMARDs exert their effects by interfering with various pro-inflammatory pathways and modulating the immune response, which helps to manage the symptoms and progression of RA (35).Biological response modifiers are another class of drugs used for RA treatment. These targeted therapies specifically inhibit molecules of the immune system such as tumor necrosis factor (TNF)-alpha inhibitors (including infliximab, etanercept, and adalimumab) and interleukin inhibitors (such as anakinra, an IL-1 inhibitor, and tocilizumab, an IL-6 receptor inhibitor) (Bodkhe et al., 2006; Bodkhe et al., 2019). These biologics help reduce inflammation and prevent joint damage by blocking specific components of the inflammatory pathways.Additionally, some DMARDs, such as gold derivatives and chloroquine, have been shown to inhibit cathepsins and proteases involved in joint inflammation and erosion. For instance, gold derivatives inhibit cathepsin K and S, potentially explaining their therapeutic benefits in RA (36).Emerging treatments and paradigms also focus on early and aggressive interventions to more effectively manage RA. This approach includes combining DMARDs with biological agents to achieve better control of the inflammation process

and prevent disease progression (37).Moreover, the role of the gut microbiota in RA is gaining attention, as changes in the gut microbial composition can influence the immune response. DMARDs might help restore the gut microbiota balance, which could further modulate the host immune system, offering a novel therapeutic angle (38).Finally, research into pain mechanisms in RA has identified that apart from joint inflammation, central nervous system (CNS) processing abnormalities contribute to chronic pain in patients. Treatments targeting these pathways, possibly through adjunct therapies such as antidepressants or antiepileptics, can be effective in managing pain, whereas other RA symptoms are controlled by DMARDs and biologics (39).

IX. MECHANISMS OF ACTION

. Inhibition of COX-2, TNF-α, IL-6
. Antioxidant and immunomodulatory effects

The mechanisms of action of the inhibition of cyclooxygenase-2 (COX-2), tumor necrosis factor-alpha (TNF-α), and interleukin-6 (IL-6) involve multiple pathways that exert anti-inflammatory, antioxidant, and immunomodulatory effects. These pathways are often targeted by various compounds and natural substances to achieve therapeutic effects under various conditions.

COX-2 Inhibition: COX-2 is an enzyme responsible for the production of pro-inflammatory prostaglandins. Its inhibition is the primary mechanism by which inflammation is reduced. Inhibition of COX-2 reduces the synthesis of pro-inflammatory eicosanoids, such as prostaglandin E2 (PGE2), thus attenuating inflammation and related symptoms, such as pain and fever. For instance, the anti-inflammatory effects of tea polyphenols involve inhibition of COX-2 expression, which reduces the severity of liver inflammation (40).

TNF-α and IL-6 Inhibition: TNF-α and IL-6 are cytokines that play significant roles in the inflammatory process. inhibitionting of their production can profoundly reduce inflammation. Compounds such as mangiferin have been shown to suppress TNF-α and IL-6, leading to decreased inflammation and oxidative stress damage in the brain following stress induction (41). Similarly, asiaticoside demonstrates the ability to inhibits LPS-induced TNF-α and IL-6 production, suggesting its potential as an anti-inflammatory agent (42).

Antioxidant Effects: Many substances that inhibit COX-2, TNF-α, and IL-6 also possess antioxidant properties. Such compounds help combat oxidative stress by neutralizing free radicals and restoring the redox balance in tissues, which is crucial in preventing cell damage during inflammatory responses. For instance, mangiferin not only inhibits pro-inflammatory mediators but also prevents oxidative damage associated with stress (41).

Immunomodulatory Effects: The modulation of immune function through these pathways is vital in autoimmune and chronic inflammatory conditions. Compounds may alter cytokine production, influence cell signaling pathways, such as NF-κB, or modify receptor interactions to exert immunomodulatory effects. For example, aurantio-obtusin demonstrates its anti-inflammatory effects by decreasing the activation of NF-κB, which plays a crucial role in cytokine production and inflammation (43).

In summary, inhibition of COX-2, TNF-α, and IL-6 with accompanying antioxidant and immunomodulatory effects can reduce inflammation and oxidative stress, modulate immune responses, and potentially offer therapeutic benefits for inflammatory and autoimmune diseases (Bajpai et al., 2018; Rahman et al., 2020; Wan et al., 2012; Márquez et al., 2011; Hou et al., 2018).

X. SYNTHETIC ANTIARTHRITIC DRUGS

Synthetic anti-arthritic drugs play a crucial role in managing rheumatoid arthritis (RA) and other inflammatory joint diseases. These drugs, often categorized as disease-modifying antirheumatic drugs (DMARDs), work through various mechanisms to alleviate symptoms and hinder disease progression.One of the cornerstone synthetic DMARDs is methotrexate (MTX), which is widely used for RA management. Despite its broad application, predicting individual patient responses to MTX remains a challenge due to heterogeneous responses influenced by genetic and non-genetic factors (44). This underscores the need for personalized therapeutic approaches for RA treatment. Another significant class of synthetic anti-arthritic drugs includes those with thiol groups, such as d-penicillamine and tiopronin. These drugs

scavenge hypochlorite, a reactive species produced by myeloperoxidase in leukocytes, and inhibit its formation. Such activities are believed to protect tissues from damage at inflamed sites, thereby contributing to therapeutic effects in patients with RA (45).Research has also explored innovative delivery systems to improve the efficacy and reduce the side effects of synthetic antiarthritic drugs. Peptide-targeted liposomal delivery systems such as ART-2-coated liposomes for dexamethasone have shown promise. This targeted approach ensures that the drug directly reaches inflamed joints, enhancing treatment effectiveness while minimizing systemic exposure and side effects (46).Marine-derived compounds and natural substances have been investigated for their anti-inflammatory properties. Cedrol, a natural compound with anti-inflammatory effects, has demonstrated anti-arthritic activity in experimental models, offering another avenue for the development of anti-arthritic therapies (47). Similarly, isopsoralen, derived from Psoralea corylifolia, targets macrophage migration inhibitory factor (MIF) to reduce inflammation and joint damage in RA models (48).Finally, understanding the broader implications of synthetic anti-arthritic drugs, such as their impact on reproductive health, where non-steroidal anti-inflammatory drugs (NSAIDs) have been linked to ovulatory failure, remains an area requiring careful clinical attention (49).

XI. CONVENTIONAL SYNTHETIC DRUGS

. NSAIDs (Ibuprofen, Diclofenac)
. Corticosteroids
. DMARDs (Methotrexate, Leflunomide)

Conventional synthetic drugs for rheumatoid arthritis (RA) include nonsteroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and disease-modifying antirheumatic drugs (DMARDs). Each class has distinct mechanisms, benefits, and adverse effects, making it suitable for different aspects of RA management.

NSAID**s**, such as ibuprofen and diclofenac, help alleviate pain and inflammation by inhibiting cyclooxygenase (COX) enzymes that produce prostaglandins, which are key mediators of inflammation. Despite their efficacy in reducing inflammatory symptoms, NSAIDs are associated with significant gastrointestinal (GI) toxicity (50). This risk escalates with higher doses, extended use, concomitant corticosteroid use, and in elderly patients or those with a history of GI issues (50). To mitigate these effects, alternative formulations, such as enteric-coated preparations and combinations with protective agents, such as misoprostol, have been explored (50). Studies indicate that sulfasalazine, a DMARD, can reduce NSAID-induced intestinal inflammation and blood loss (51).

Corticosteroids such as prednisone have potent anti-inflammatory and immunosuppressive effects, making them valuable for rapid symptom control in RA (52). However, their efficacy is dose-dependent, and higher doses are associated with significant risks including serious infections (53). Even low-dose corticosteroid therapy presents infection risks similar to biological therapies (53). Because of these concerns, corticosteroids are often used short-term and in combination with other antirheumatic agents, including NSAIDs and DMARDs, to optimize therapeutic outcomes while minimizing adverse effects (54).

DMARD**s**, such as methotrexate and leflunomide, aim to alter the disease course by targeting the underlying inflammatory processes. Methotrexate is often the first-line therapy for RA because of its efficacy and safety profile (55). DMARDs vary significantly in toxicity; for instance, hydroxychloroquine presents lower toxicity than other drugs such as methotrexate or azathioprine (56). Although DMARDs typically have a slower onset of action, they are crucial in sustaining long-term disease remission and are sometimes supplemented with corticosteroids to manage acute flares (57). Despite their effectiveness, certain DMARDs carry infection risks, necessitating careful monitoring (53).

NSAIDs, corticosteroids, and DMARDs play distinct roles in the management of RA. NSAIDs are primarily used for symptom relief, corticosteroids are used for their rapid action, and DMARDs are vital for modifying the disease progression. Each class carries specific risks, particularly concerning GI toxicity, infection, and long-term adverse effects, which guide the selection and combination of therapies based on individual patient profiles and disease severity.

Biological therapies

. Anti-TNF agents (Etanercept, Infliximab)

. IL-6 inhibitors (Tocilizumab)
. JAK inhibitors (Tofacitinib)

Biological therapies have emerged as transformative treatments for immune-mediated diseases, particularly owing to their targeted mechanisms of action. Among these, anti-TNF agents, IL-6 inhibitors, and JAK inhibitors are prominent because of their roles in addressing inflammatory and autoimmune conditions.

Anti-tumor necrosis factor (TNF) agents such as Etanercept and Infliximab are crucial in managing conditions such as rheumatoid arthritis, ankylosing spondylitis, and inflammatory bowel diseases. TNF is a cytokine involved in systemic inflammation and its overproduction is a hallmark of these diseases. Etanercept is a fusion protein that acts as a decoy receptor for TNF, thereby preventing its interaction with cell-surface receptors. Infliximab, a monoclonal antibody, directly binds to TNF and neutralizes its effects. Both therapies significantly improve patient outcomes by reducing inflammation and slowing disease progression.

IL-6 Inhibitors: Interleukin-6 (IL-6) is another cytokine involved in immune responses and inflammation. Tocilizumab, an IL-6 receptor antagonist, has been effectively used to treat rheumatoid arthritis and giant cell arteritis. By blocking IL-6 signaling, tocilizumab reduces inflammation and other symptoms associated with these diseases. Its use is particularly beneficial in patients who do not respond adequately to TNF inhibitors, providing an alternative mechanism for controlling disease activity.

Janus kinase (JAK) inhibitors, such as tofacitinib, offer another line of therapy for autoimmune conditions. These small molecules inhibit the JAK-STAT signaling pathway, which is crucial for the signaling of various cytokines. By blocking this pathway, JAK inhibitors can reduce immune system activity and alleviate symptoms of diseases such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. Tofacitinib, specifically, has been shown to be effective in patients who have not responded to traditional DMARDs (disease-modifying antirheumatic drugs).

Collectively, these biological therapies represent a sophisticated approach to managing complex immune-mediated diseases, offering targeted treatment strategies that go beyond traditional medications and often lead to an improved quality of life for patients. While I cannot generate a full essay, this overview provides insight into the evolving landscape of biological therapies in immune-mediated diseases.

XII. CHALLENGES AND SIDE EFFECTS

GI issues, liver toxicity, immunosuppression

Rheumatoid arthritis (RA) is a chronic autoimmune disease treated with various pharmacological interventions such as nonsteroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, disease-modifying antirheumatic drugs (DMARDs), and biologics. However, these treatments often encounter significant challenges and side effects, including gastrointestinal (GI) issues, liver toxicity, and immunosuppression.

Gastrointestinal Issues: GI issues, particularly perforations, are a notable risk factor in patients with RA. Traditional treatments, such as glucocorticoids and NSAIDs, increase the risk of GI perforation due to their effects on the gastrointestinal lining. Although biologics have been a significant advancement in RA treatment, certain biologics, especially those inhibiting the interleukin (IL)-6 cytokine receptor, have also been linked to an increased risk of GI perforations. This risk is compounded by the inclusion of Janus kinase inhibitors, which may contribute to perforations through IL-6 signaling interference (Jagpal and Curtis, 2018; Schuna and Megeff, 2000).

Liver Toxicity: The use of methotrexate, a common DMARD for RA, is often associated with hepatotoxicity and presents a major concern for patients. Research on alternative therapies with lower toxicity profiles is ongoing. For instance, silibinin has shown promise in alleviating methotrexate-induced hepatotoxicity by offering both hepatoprotective and antioxidant benefits. Silibinin has been shown to restore antioxidant balance and minimize liver damage, demonstrating its potential as a complementary therapy to reduce liver toxicity (58).

Immunosuppression: RA medications, particularly glucocorticoids and biologics, carry the risk of immunosuppression, which increases the susceptibility to infections. Tumor necrosis factor (TNF) inhibitors, a class of biologics, are associated

with a heightened risk of serious infection. Similarly, Janus kinase inhibitors also present an increased risk of infections such as herpes zoster. The risk of infection is dose-dependent with glucocorticoids; however, even low doses can elevate the risk to levels comparable to those of biological therapies (Riley and George, 2021; Riley and George, 2021).

In summary, while significant advances in RA treatment have improved disease management and patient outcomes, challenges such as GI issues, liver toxicity, and immunosuppression due to these treatments remain. Continued research on therapies with fewer side effects and interventions that address the underlying disease mechanisms without compromising patient safety is crucial for the holistic management of RA.

Molecular Targets and Inflammatory Pathways

. Role of NF-κB, MAPK, JAK-STAT pathways
. Inflammatory cytokines (TNF-α, IL-1β, IL-6)
. New targets: NLRP3 inflammasome, PI3K/Akt pathway

Understanding the roles of specific molecular targets and inflammatory pathways is crucial for managing rheumatoid arthritis (RA), a chronic autoimmune condition characterized by joint inflammation. Several key pathways and cytokines, including the NF-κB, MAPK, and JAK-STAT pathways, are important in the pathogenesis and treatment of RA.

The Janus kinase (JAK) pathway plays a crucial role in the pathophysiology of RA. Various cytokines activate JAKs, which leads to inflammation and joint destruction. JAK inhibitors such as tofacitinib and baricitinib have emerged as effective treatments, especially for patients who do not respond to traditional DMARDs. These inhibitors block JAK1, JAK2, and JAK3, disrupting the signaling that leads to inflammation (Nakayamada et al., 2016; Scott, 2013).

Inflammatory cytokines such as TNF-α, IL-1β, and IL-6 are pivotal in RA. Therapies targeting these cytokines, such as TNF inhibitors (etanercept, infliximab, and adalimumab) and IL-1 receptor antagonists, have demonstrated significant efficacies. They reduce clinical symptoms and mitigate joint damage, but they also have safety concerns such as increased infection risk (Fleischmann et al., 2004; Maini and Taylor, 2000).

The NF-κB and MAPK pathways, such as JAK-STAT, are involved in cellular responses to cytokines and promote inflammation. Targeting these pathways offers a strategy for modulating immune responses that are naturally involved in RA pathogenesis (59).

Recently, the NLRP3 inflammasome and the PI3K/Akt pathway have gained attention as potential therapeutic targets. NLRP3 inflammasome is involved in IL-1β maturation and secretion, making it a critical component of inflammation. Inhibitors targeting NLRP3 could potentially ameliorate inflammatory processes in RA (60).

In conclusion, the therapeutic landscape for RA includes targeting traditional pathways, such as JAK-STAT, and newly identified targets, such as the NLRP3 inflammasome. While current therapies improve patient outcomes, ongoing research on these pathways and molecular targets continues to hold promise for more effective and safer treatment options. For comprehensive management, personalized approaches that consider the patient-specific pathway and cytokine profile may be the future direction of RA therapy. While I could not generate a full essay, the information provided highlights the current understanding of these pathways and targets in RA treatment.

Comparative Analysis: Natural vs Synthetic Therapies

. Efficacy and safety profile
. Patient compliance
. Long-term benefits and drawbacks
. Synergistic approaches (combination therapies)

When comparing natural and synthetic therapies for rheumatoid arthritis (RA), several aspects, including efficacy, safety, patient compliance, long-term benefits, and the potential for synergistic approaches, must be considered.

XIII. EFFICACY AND SAFETY PROFILE

In RA, natural therapies often pertain to lifestyle changes and holistic treatments, whereas synthetic therapies involve pharmacological interventions. A randomized controlled trial evaluating educational–

behavioral joint protection programs (a form of natural therapy) found improved adherence and functional ability in patients with RA over a long period compared to standard educational methods (61). In contrast, synthetic therapies, such as naltrexone and acamprosate, used in alcohol dependency treatment, demonstrated significant efficacy but were often associated with side effects that could impact long-term adherence and safety profiles (62).

XIV. PATIENT COMPLIANCE

Patient compliance is crucial to the effectiveness of both natural and synthetic therapies. For RA, adherence to joint protection programs leads to better health outcomes (61). However, challenges remain in maintaining compliance with complex treatment regimens, as seen in the treatment of conditions such as multiple sclerosis, where nonadherence is a common issue (63). Long-acting injectable agents, although demonstrating improved adherence to HIV-1, highlight that adherence can vary significantly with treatment type and administration method (64).

Long-term Benefits and Drawbacks

The long-term benefits of natural therapies include improvements in functional ability and adherence to nonpharmacological strategies. However, they may not provide the immediate symptomatic relief that synthetic drugs offer. For synthetic therapies, efficacy is often dependent on consistent adherence, as demonstrated by the effectiveness of antiretrovirals against HIV-1 (65). Synthetic drugs may have adverse effects that could hinder their long-term use, thus affecting patient compliance and therapy success.

Synergistic Approaches (Combination Therapies)

Synergistic approaches that combine both natural and synthetic therapies can potentially improve the outcomes of RA. The integration of educational behavioral programs with pharmacotherapy may enhance compliance and efficacy. For example, psychoeducational interventions have been successful in enhancing long-term adherence and therapeutic outcomes in other chronic diseases, suggesting a viable model for RA treatment (65). Understanding the economic implications of adherence, as explored in osteoporosis treatment, suggests that improving compliance could enhance the cost-effectiveness of combination therapies (66).

In conclusion, both natural and synthetic therapies offer distinct advantages and challenges, particularly concerning their efficacy, safety, and patient adherence. Synergistic approaches that combine the strengths of both may present a viable pathway for improving the treatment outcomes of rheumatoid arthritis. While I cannot generate a full essay, here is a comprehensive analysis based on the available literature regarding these therapies for RA.

Current Research Trends and Clinical Trials

. Recent preclinical and clinical studies
. Nanoparticle-based delivery of natural compounds
. Biosimilars and next-gen biologic

The development of rheumatoid arthritis (RA) has significantly influenced recent advances in the treatment of nanoparticle-based delivery systems and biosimilars.

Nanoparticle-based Delivery Systems

Nanoparticles offer targeted drug delivery, improve drug bioavailability, and reduce systemic side effects, which are crucial in RA treatment (67). Recent studies have explored the use of various nanoparticles in the treatment of RA.

1. Dextran Sulfate-based Nanomicelles:
2. These are engineered for enzyme-sensitive delivery, targeting the scavenger receptor (SR-A) of macrophages to deliver Celastrol, showing enhanced anti-inflammatory activity with lower systemic toxicity (67).Matrix Metalloproteinase (MMP)-Responsive Lipid Nanoparticles:
3. These nanoparticles use PEGylation to enhance biocompatibility, circulate longer in the bloodstream, and preferentially target inflammatory sites, providing controlled dexamethasone release in response to elevated MMPs, reducing joint swelling and inflammatory markers (68).Biomimetic Nanomedicines:
4. These nanomedicines utilize endogenous materials to effectively target RA sites, leveraging the inflammatory microenvironment for drug release (69).Multifunctional Gold Half-Shell Nanoparticles:

These combine chemo-photothermal treatment with methotrexate using infrared light to enhance drug release, significantly improving therapeutic outcomes and minimizing side effects (70).

Biosimilars in Rheumatoid Arthritis

Biosimilars are biological products that are highly similar to approved reference biologics, but have potential cost benefits due to lower development and marketing costs. For RA, biosimilars mainly focus on biologics that inhibit tumor necrosis factor (TNF) such as adalimumab and etanercept.

1. Adalimumab Biosimilars:
2. With patent expiration of adalimumab, several biosimilars have entered the market, showing similar efficacy, safety, and immunogenicity compared to the original biologic. Examples include ABP 501, BI 695501, and SB5, which successfully meet the equivalence criteria (Lu et al., 2021; Zhao et al., 2018). Etanercept Biosimilars:
3. Two such biosimilars, SB4 and GP2015, have shown promising results in terms of efficacy and safety, although continuous real-world data are necessary to fully assess their impact (71).Impact on Healthcare:

Biosimilars are expected to reduce healthcare costs due to their lower price and increased accessibility for patients. Effective communication between health care providers (HCPs) and patients is essential to mitigate any nocebo effects arising from negative perceptions of biosimilars (Smolen et al., 2021; Kim et al., 2020).

Overall, these developments underscore the significance of nanotechnology in enhancing drug delivery systems for RA, while biosimilars provide a promising alternative to pricier biological treatments, supporting wider access and evolving treatment strategies in rheumatoid arthritis management.

Future Perspectives

. Personalized medicine in arthritis treatment
. AI and computational drug screening
. Integration of nutraceuticals in mainstream therapy

The future of personalized medicine in arthritis treatment shows significant promise as it shifts towards more tailored therapeutic strategies. Personalized medicine aims to adapt treatment plans based on individual patient characteristics such as genetic makeup, lifestyle, and specific disease profiles. This approach is expected to enhance the treatment efficacy and minimize adverse effects.

Recent advancements in genetic and molecular research have paved the way for the identification of specific biomarkers associated with various forms of arthritis. These biomarkers can provide insights into disease mechanisms and progression, allowing for early diagnosis and targeted intervention. The integration of genomic data with clinical practice, facilitated by artificial intelligence and machine learning algorithms, can be used to analyze vast amounts of data to predict disease outcomes and tailor treatments accordingly.

Additionally, the development of biological agents has revolutionized the treatment landscape for arthritis. These agents are designed to target specific components of the immune system, reduce inflammation, and halt joint damage. Personalized medicine seeks to optimize the use of these biologics by identifying patients who are most likely to benefit from them, based on genetic and molecular profiles.

Furthermore, advancements in wearable technology and remote monitoring tools can track disease activity and patient response to treatment in real-time. These technologies can provide valuable data that can be used to adjust treatment plans on an ongoing basis, thereby improving patient outcomes and quality of life.

Overall, the future of personalized medicine for arthritis treatment is centered on the integration of advanced technologies, genetic research, and patient-centered care. These innovations promise to transform the management of arthritis and offer hope for more effective and individualized therapies.

XV. CONCLUSION

The field of anti-arthritic therapies has seen significant advancements in recent years, with promising developments in both natural and synthetic approaches. This review highlights the following key areas.

1. Natural compounds, such as curcumin, boswellic acid, and resveratrol, have demonstrated potent anti-inflammatory and antioxidant effects that may help manage arthritis symptoms. Traditional medicine systems, such as Ayurveda and TCM, offer

polyherbal formulations with potential synergistic benefits.

2. Synthetic drugs, including NSAIDs, DMARDs, and biologics, remain the mainstay of treatment for arthritis. New targeted therapies, such as JAK inhibitors, have shown improved efficacy in modulating inflammatory pathways.

3. Emerging research has focused on novel drug delivery systems, such as nanoparticle-based approaches, to enhance the bioavailability and reduce the side effects of both natural and synthetic compounds.

4. The development of biosimilars offers the potential for more cost-effective biological treatments, increasing accessibility for patients.

5. Personalized medicine approaches leveraging genetic and biomarker data may allow for more tailored and effective treatment strategies in the future.

6. The integration of nutraceuticals and natural compounds as adjunct therapies to conventional treatments shows promise for enhancing overall efficacy and patient outcomes.

Although significant progress has been made, challenges remain in terms of long-term safety, patient compliance, and optimization of combination therapies. Further clinical research is needed to validate the efficacy of many natural compounds and to refine personalized treatment protocols. Our understanding of the molecular mechanisms underlying arthritis, as well as the potential for developing more targeted and effective antiarthritic therapies, continues to grow. The integration of natural and synthetic approaches, coupled with advances in precision medicine, offers an exciting path for improving the management of arthritis and enhancing the quality of life of patients.

REFERENCES

[1] Herrero-Cervera A, Soehnlein O, Kenne E. Neutrophils in chronic inflammatory diseases. Cellular & Molecular Immunology. 2022 Jan 17;19(2):177–91.

[2] Chanda D, Ha H, Lee IK. Editorial: The role of oxidative stress and systemic inflammation in diabetes and chronic kidney disease. Frontiers in Endocrinology. 2023 Aug 21;14.

[3] Van De Vyver M. Immunology of chronic low-grade inflammation: relationship with metabolic function. Journal of Endocrinology. 2023 Jan 23;257(1).

[4] Radovani B, Gudelj I. N-Glycosylation and Inflammation; the Not-So-Sweet Relation. Frontiers in immunology. 2022 Jun 27;13.

[5] Chiurchiù V, Maccarrone M, Leuti A. Bioactive Lipids and Chronic Inflammation: Managing the Fire Within. Frontiers in Immunology. 2018 Jan 29;9(17).

[6] Andersen C. Bioactive Egg Components and Inflammation. Nutrients. 2015 Sep 16;7(9):7889–913.

[7] Ferrer MD, Busquets-Cortés C, Capó X, Sureda A, Pons A, Tur JA, et al. Cyclooxygenase-2 Inhibitors as a Therapeutic Target in Inflammatory Diseases. Current Medicinal Chemistry. 2019 Sep 2;26(18):3225–41.

[8] Kumar M, Murugesan S, Ibrahim N, Elawad M, Al Khodor S. Predictive biomarkers for anti-TNF alpha therapy in IBD patients. Journal of translational medicine. 2024 Mar 16;22(1).

[9] Li HJ, Chang DC, Wu NL, Hsiao CY, Hung CF, Pu CM. Chrysin alleviates imiquimod-induced psoriasis-like skin inflammation and reduces the release of CCL20 and antimicrobial peptides. Scientific Reports. 2020 Feb 19;10(1).

[10] Kim SW, Jeong SH, Kim JU, Kim MH, Lee W, Lee CJ, et al. Zanthoxylum piperitum Benn. Attenuates Monosodium Urate-Induced Gouty Arthritis: A Network Pharmacology Investigation of Its Anti-Inflammatory Mechanisms. Pharmaceuticals (Basel, Switzerland). 2024 Dec 29;18(1):29.

[11] Figueiredo CS, Viana TT, Roseira ES, Passos LCS, Fernandez MG, Silveira MAD, et al. Inflammation in Coronary Atherosclerosis: Insights into Pathogenesis and Therapeutic Potential of Anti-Inflammatory Drugs. Pharmaceuticals. 2023 Sep 1;16(9):1242.

[12] Benalaya I, Alves G, Lopes J, Silva LR. A Review of Natural Polysaccharides: Sources, Characteristics, Properties, Food, and Pharmaceutical Applications. International journal of molecular sciences. 2024 Jan 22;25(2):1322.

[13] Xie Y, Lu H, Huang J, Xie H. Natural Materials for Sustainable Organic Solar Cells: Status and

Challenge. Advanced Functional Materials. 2023 Jan 23;33(15):2213910.

[14] Song N, Yang YW. Applications of pillarenes, an emerging class of synthetic macrocycles. Science China Chemistry. 2014 Aug 4;57(9):1185–98.

[15] Soliman BG, Nguyen AK, Gooding JJ, Kilian KA. Advancing Synthetic Hydrogels through Nature-Inspired Materials Chemistry. Advanced materials (Deerfield Beach, Fla). 2024 Jul 1;36(42).

[16] Kim CS, Oh J, Lee TH. Structure elucidation of small organic molecules by contemporary computational chemistry methods. Archives of Pharmacal Research. 2020 Oct 29;43(11):1114–27.

[17] Bahlai CA, Xue Y, Mccreary CM, Hallett RH, Schaafsma AW. Choosing Organic Pesticides over Synthetic Pesticides May Not Effectively Mitigate Environmental Risk in Soybeans. PLoS ONE. 2010 Jun 22;5(6):e11250.

[18] Baig S, Direnzo DD. Complementary and Alternative Medicine Use in Rheumatoid Arthritis. Current Rheumatology Reports. 2020 Aug 26;22(10).

[19] Lin J, Liu J, O'Fee A, Pandey C, Benna-Doyle S, Maunder A, et al. The effectiveness and safety of lifestyle medicine and integrative therapies in inflammatory arthritis: an umbrella review using a hierarchical evidence gathering approach. Frontiers in medicine. 2024 Mar 13;11.

[20] Sharma D, Chaubey P, Suvarna V. Role of natural products in alleviation of rheumatoid arthritis-A review. Journal of Food Biochemistry. 2021 Feb 24;45(4).

[21] Samy BA, Raman K, Velayutham S, Senthilkumar N, Thirumalaivasan N, Kanagaraj K, et al. Natural product extract fractions as potential arthritis treatments: A detailed analysis using in-silico, in-vivo, and in-vitro methods. International immunopharmacology. 2025 Jan 1;144:113595.

[22] Lin YC, Jamison RN, Wan L. Using Integrative Medicine in Pain Management: An Evaluation of Current Evidence. Anesthesia & Analgesia. 2017 Dec 1;125(6):2081–93.

[23] Maouche A, Boumediene K, Baugé C. Bioactive Compounds in Osteoarthritis: Molecular Mechanisms and Therapeutic Roles. International journal of molecular sciences. 2024 Oct 30;25(21):11656.

[24] Kciuk M, Garg A, Rohilla M, Chaudhary R, Dhankhar S, Dhiman S, et al. Therapeutic Potential of Plant-Derived Compounds and Plant Extracts in Rheumatoid Arthritis-Comprehensive Review. Antioxidants (Basel, Switzerland). 2024 Jun 27;13(7):775.

[25] Weinstabl H, Lautens M, Suhartono M, Qureshi Z. Total Synthesis of (+)-Linoxepin by Utilizing the Catellani Reaction. Angewandte Chemie International Edition. 2013 Apr 16;52(20):5305–8.

[26] Zielińska M, Dereń K, Stępień AE, Polak-Szczybyło E. The Role of Bioactive Compounds of Nigella sativa in Rheumatoid Arthritis Therapy-Current Reports. Nutrients. 2021 Sep 25;13(10):3369.

[27] Septama AW, Al Chaira DM, Salim E, Nainu F, Nasution HR, Marwa Rani HL, et al. Mechanistic insights into anti-inflammatory and immunosuppressive effects of plant secondary metabolites and their therapeutic potential for rheumatoid arthritis. Phytotherapy research : PTR. 2024 Apr 10;38(6):2931–61.

[28] Qiang R, Shi X, Qiu H, Fan Z, Huang H, Chen J, et al. Carbon Quantum Dots Derived from Herbal Medicine as Therapeutic Nanoagents for Rheumatoid Arthritis with Ultrahigh Lubrication and Anti-inflammation. ACS Applied Materials & Interfaces. 2023 Aug 3;15(32):38653–64.

[29] Ibrahim AS, Shaza A, Laurence A, Elie BS, Toni H, Fadi H, et al. Over-the-Counter Anti-inflammatory Supplements for Adjunctive Rheumatoid Arthritis Therapy: A Comprehensive Narrative Review. Aging and disease. 2024 Jan 1;

[30] Oliviero F, Zamudio-Cuevas Y, Scanu A, Punzi L, Spinella P. Anti-inflammatory effects of polyphenols in arthritis. Journal of the Science of Food and Agriculture. 2017 Oct 9;98(5):1653–9.

[31] Prasad S, Kulshreshtha A, Lall R, Gupta SC. Inflammation and ROS in arthritis: management by Ayurvedic medicinal plants. Food & Function. 2021 Jan 1;12(18):8227–47.

[32] Funk JL, Chen G, Frye JB, Lantz RC, Sólyom AM, Jolad SD, et al. Turmeric extracts containing curcuminoids prevent experimental

rheumatoid arthritis. Journal of Natural Products. 2006 Feb 4;69(3):351–5.

[33] Li TP, Yan GL, Sun H, Wang XJ, Miao JH, Zhang AH, et al. Applications and potential mechanisms of herbal medicines for rheumatoid arthritis treatment: a systematic review. RSC Advances. 2019 Jan 1;9(45):26381–92.

[34] Zhou X, Seto SW, Chang D, Bensoussan A, Chan K, Kiat H, et al. Synergistic Effects of Chinese Herbal Medicine: A Comprehensive Review of Methodology and Current Research. Frontiers in Pharmacology. 2016 Jul 12;7.

[35] Gaffo A, Curtis JR, Saag KG. Treatment of rheumatoid arthritis. American Journal of Health-System Pharmacy. 2006 Dec 15;63(24):2451–65.

[36] Weidauer E, Cherny M, James MNG, Yasuda Y, Biswal BK, Brömme D. Effects of disease-modifying anti-rheumatic drugs (DMARDs) on the activities of rheumatoid arthritis-associated cathepsins K and S. Biological Chemistry. 2007 Jan 1;388(3).

[37] Fries JF. Current treatment paradigms in rheumatoid arthritis. Rheumatology. 2000 Jun 1;Suppl 39 1(Suppl 1):30–5.

[38] Bodkhe R, Balakrishnan B, Taneja V. The role of microbiome in rheumatoid arthritis treatment. Therapeutic Advances in Musculoskeletal Disease. 2019 Jan 1;11(Suppl 3):1759720X1984463.

[39] Zhang A, Lee YC. Mechanisms for Joint Pain in Rheumatoid Arthritis (RA): from Cytokines to Central Sensitization. Current osteoporosis reports. 2018 Aug 20;16(5):603–10.

[40] Rahman SU, Zhu L, Khan IM, Junejo SA, Chu X, Zhang Y, et al. Tea polyphenols attenuate liver inflammation by modulating obesity-related genes and down-regulating COX-2 and iNOS expression in high fat-fed dogs. BMC Veterinary Research. 2020 Jul 8;16(1).

[41] Márquez L, Madrigal JLM, García-Bueno B, Leza JC. Mangiferin decreases inflammation and oxidative damage in rat brain after stress. European Journal of Nutrition. 2011 Oct 7;51(6):729–39.

[42] Wan J, Zhang Z, Zhang L, Gong X, Jiang R. Antipyretic and Anti-inflammatory Effects of Asiaticoside in Lipopolysaccharide-treated Rat through Up-regulation of Heme Oxygenase-1. Phytotherapy Research. 2012 Sep 12;27(8):1136–42.

[43] Hou J, Zhang Y, Wang S, Zhao S, Huo M, Li X, et al. Anti-Inflammatory Effects of Aurantio-Obtusin from Seed of Cassia obtusifolia L. through Modulation of the NF-κB Pathway. Molecules. 2018 Nov 27;23(12):3093.

[44] Romão VC, Canhão H, Fonseca JE. Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs? BMC Medicine. 2013 Jan 23;11(1).

[45] Cuperus RA, Wever R, Muijsers AO. Antiarthritic drugs containing thiol groups scavenge hypochlorite and inhibit its formation by myeloperoxidase from human leukocytes. A therapeutic mechanism of these drugs in rheumatoid arthritis? Arthritis & Rheumatism. 1985 Nov 1;28(11):1228–33.

[46] Meka RR, Venkatesha SH, Acharya B, Moudgil KD. Peptide-targeted liposomal delivery of dexamethasone for arthritis therapy. Nanomedicine (London, England). 2019 Apr 2;14(11):1455–69.

[47] Forouzanfar F, Ghazavi H, Pourbagher-Shahri AM. Evaluation of Antiarthritic and Antinociceptive Effects of Cedrol in a Rat Model of Arthritis. Oxidative Medicine and Cellular Longevity. 2022 Apr 25;2022(1):1–10.

[48] Han Y, Zhang Y, Li Y, Fan H, Li S, Zhang R, et al. Isopsoralen ameliorates rheumatoid arthritis by targeting MIF. Arthritis Research & Therapy. 2021 Sep 17;23(1).

[49] Smith G, Roberts R, Hall C, Nuki G. Reversible ovulatory failure associated with the development of luteinized unruptured follicles in women with inflammatory arthritis taking non-steroidal anti-inflammatory drugs. Rheumatology. 1996 Jan 1;35(5):458–62.

[50] Willett LR, Carson JL, Strom BL. Epidemiology of gastrointestinal damage associated with nonsteroidal anti-inflammatory drugs. Drug Safety. 1994 Feb 1;10(2):170–81.

[51] Hayllar J, Price AB, Bjarnason I, Macpherson A, Smith T, Gumpel M. Nonsteroidal antiinflammatory drug-induced small intestinal inflammation and blood loss. Effects of sulfasalazine and other disease-modifying

antirheumatic drugs. Arthritis & Rheumatism. 1994 Dec 1;37(8):1146–50.

[52] Li YJ, Chen Z. Cell-based therapies for rheumatoid arthritis: opportunities and challenges. Therapeutic Advances in Musculoskeletal Disease. 2022 Jan 1;14(Suppl 5):1759720X2211002.

[53] Riley TR, George MD. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 2021 Feb 1;7(1):e001235.

[54] Li X, Dubois DC, Song D, Almon RR, Jusko WJ, Chen X. Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen. Drug metabolism and disposition: the biological fate of chemicals. 2017 Apr 17;45(7):834–45.

[55] Smolen J, Nam J, Van Der Heijde D, Landewé R, Van Riel P, Van Vollenhoven R, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases. 2010 May 1;69(6):964–75.

[56] Fries JF, Williams CA, Ramey D, Bloch DA. The relative toxicity of disease-modifying antirheumatic drugs. Arthritis & Rheumatism. 1993 Mar 1;36(3):297–306.

[57] Abbasi M, Mousavi MJ, Aslani S, Bezvan MH, Jamalzehi S, Mohammadi H, et al. Strategies toward rheumatoid arthritis therapy; the old and the new. Journal of Cellular Physiology. 2018 Dec 7;234(7):10018–31.

[58] Khawaja G, El-Orfali Y. Silibinin's Effects against Methotrexate-Induced Hepatotoxicity in Adjuvant-Induced Arthritis Rat Model. Pharmaceuticals. 2024 Mar 28;17(4):431.

[59] Zhou S, Zou H, Huang G, Chen G. Synthesis and Biological Activities of Chemical Drugs for the Treatment of Rheumatoid Arthritis. Topics in Current Chemistry. 2019 Sep 28;377(5).

[60] Huang J, Li Z, Fu X, Huang Y, Chen X, Liang C. Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis. Frontiers in Immunology. 2021 Jul 9;12(9).

[61] Hammond A, Freeman K. The long-term outcomes from a randomized controlled trial of an educational–behavioural joint protection programme for people with rheumatoid arthritis. Clinical Rehabilitation. 2004 Aug 1;18(5):520–8.

[62] Carmen B, Angeles M, Ana M, María AJ. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction. 2004 May 12;99(7):811–28.

[63] Klauer T, Zettl UK. Compliance, adherence, and the treatment of multiple sclerosis. Journal of Neurology. 2008 Dec 1;255(S6):87–92.

[64] Wang W, Huang X, Duan W, Zhao S, Guo C, Wang W, et al. Safety and Efficacy of Long-Acting Injectable Agents for HIV-1: Systematic Review and Meta-Analysis. JMIR Public Health and Surveillance. 2023 Jul 27;9:e46767.

[65] Tuldr?? A, Bay??S R, Romeu J, Arn?? A, Burger D, Ferrer MJ, et al. Prospective Randomized Two-Arm Controlled Study to Determine the Efficacy of a Specific Intervention to Improve Long-Term Adherence to Highly Active Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes. 2000 Nov 1;221–8.

[66] Kanis JA, Reginster JY, Cooper C, Rizzoli R, Rabenda V, Hiligsmann M. Partial adherence: a new perspective on health economic assessment in osteoporosis. Osteoporosis International. 2011 May 27;22(10):2565–73.

[67] Yu C, Liu H, Guo C, Chen Q, Su Y, Guo H, et al. Dextran sulfate-based MMP-2 enzyme-sensitive SR-A receptor targeting nanomicelles for the treatment of rheumatoid arthritis. Drug Delivery. 2022 Feb 4;29(1):454–65.

[68] He L, Fang J, Liang W, Fan D, Wang Q. Matrix Metalloproteinase-Responsive PEGylated Lipid Nanoparticles for Controlled Drug Delivery in the Treatment of Rheumatoid Arthritis. ACS Applied Bio Materials. 2020 Apr 9;3(5):3276–84.

[69] Li C, Zheng X, Hu M, Jia M, Jin R, Nie Y. Recent progress in therapeutic strategies and biomimetic nanomedicines for rheumatoid arthritis treatment. Expert Opinion on Drug Delivery. 2022 Jul 5;19(8):883–98.

[70] Lee SM, Ha YJ, Park YN, Yoo KH, Lee SK, Kim HJ, et al. Targeted Chemo-Photothermal Treatments of Rheumatoid Arthritis Using Gold

Half-Shell Multifunctional Nanoparticles. ACS Nano. 2012 Dec 7;7(1):50–7.

[71] Chadwick L, Zhao S, Mysler E, Moots RJ. Review of Biosimilar Trials and Data on Etanercept in Rheumatoid Arthritis. Current Rheumatology Reports. 2018 Nov 9;20(12).